Immunome (NASDAQ:IMNM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm presently has a $33.00 price target on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 11.07% from the stock’s previous close.
According to Zacks, “Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States. “
Shares of IMNM traded down $0.01 on Tuesday, reaching $29.71. The company’s stock had a trading volume of 64,154 shares, compared to its average volume of 267,457. The company’s 50 day moving average price is $32.68. Immunome has a 12-month low of $9.27 and a 12-month high of $63.78.
Several institutional investors and hedge funds have recently bought and sold shares of IMNM. BlackRock Inc. purchased a new position in shares of Immunome in the fourth quarter worth approximately $695,000. Granite Point Capital Management L.P. purchased a new position in Immunome during the fourth quarter valued at approximately $645,000. New York State Common Retirement Fund purchased a new position in Immunome during the fourth quarter valued at approximately $53,000. Cerity Partners LLC purchased a new position in Immunome during the fourth quarter valued at approximately $1,186,000. Finally, Northern Trust Corp purchased a new position in Immunome during the fourth quarter valued at approximately $245,000.
Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
Recommended Story: How are dividend achievers different from dividend aristocrats?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.